For the Inventor, By the Inventor

Enter assignee name

Senju Pharmaceutical Co., Ltd.

USPTO Granted Patents = 229

CIPO Patents = 7

EPO Patents = 50

Trademarks = 4

Forward Citations = 1,644

Loading Chart...

Loading Chart...

233 inventors (with patents filed for the assignee):

Kazumi Ogata (46 out of 48 patents)

Takahiro Sakaue (27 out of 27 patents)

Shirou Sawa (19 out of 19 patents)

4. Jun Inoue (19 out of 20 patents)

5. Mitsuyoshi Azuma (15 out of 17 patents)

6. Koji Doi (14 out of 14 patents)

7. Takahiro Ogawa (13 out of 20 patents)

8. Shigeru Kinoshita (11 out of 25 patents)

9. Noriko Koizumi (11 out of 22 patents)

10. Masayuki Nakamura (9 out of 9 patents)

11. Katsuhiro Inada (9 out of 11 patents)

12. Kenichi Yoshida (9 out of 9 patents)

13. Shuhei Fujita (8 out of 8 patents)

14. Takeshi Nakajima (8 out of 72 patents)

15. Akira Ohtori (8 out of 8 patents)

Core Competencies:

Retinal Ganglion Cell Death Inhibitor

PACAP Stabilized Peptide

Anionic Drug-Containing Ophthalmic Device

Corneal Endothelial Cell Adhesion

Neuroprotective Peptide

Aqueous Liquid Preparations

Hydrogel Contact Lens

Corneal Endothelial Proliferation

Bodily Fluid Collection Device

Intraocular Surgery System

Therapeutic Drug for Corneal Disorders

Sustained Drug Release

229 patents: Sort by Forward Citations

1. 12502375 - Pharmaceutical drug containing heterocyclidene acetamide derivative (2025-12-23),

2. 12427147 - Retinal ganglion cell death inhibitor (2025-09-30),

3. 12304932 - PACAP stabilized peptide (2025-05-20),

4. 12161652 - Anionic drug-containing ophthalmic device (2024-12-10),

5. 12137885 - Bodily fluid collection device (2024-11-12),

6. 12024714 - Method for preparation of retinal ganglion cells (2024-07-02),

7. 11918630 - Treatment of retina and nerve using laminin (2024-03-05),

8. 11857544 - Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases (2024-01-02),

9. 11844776 - Composition for treatment and/or prevention of peripheral nerve disorder (2023-12-19),

10. 11839618 - Agent for promoting corneal endothelial cell adhesion (2023-12-12),

11. 11730722 - Corneal endothelium ECM therapeutic medicaments (2023-08-22),

12. 11633477 - Treatment of cornea using laminin (2023-04-25),

13. 11633404 - Agent for promoting corneal endothelial cell adhesion (2023-04-25),

14. 11439589 - Emulsion eyedrops (2022-09-13),

15. 11382904 - Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium (2022-07-12),

Senju Pharmaceutical Co., Ltd. is a leading Japanese company specializing in the research, development, and marketing of innovative pharmaceutical products. With a focus on ophthalmic medicines, Senju Pharmaceutical is committed to improving people's quality of life through the advancement of healthcare. Through cutting-edge technology and a dedicated research team, the company aims to provide effective and safe solutions for various medical needs. Visit their website for more information about their products and initiatives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

229 Patents

#69 in Osaka

#618 in Japan

#3,631 in the World

Senju Pharmaceutical Co., Ltd.

Forward Citations = 1,644

233 inventors:

Kazumi Ogata (46 out of 48 patents)

Takahiro Sakaue (27 out of 27 patents)

Shirou Sawa (19 out of 19 patents)

4. Jun Inoue (19 out of 20 patents)

5. Mitsuyoshi Azuma (15 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…